Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The study is a prospective, placebo controlled, randomized study to evaluate the impact of an
anti-inflammatory challenge (Infliximab Treatment) on reward circuitry, motivational
deficits, and negative symptoms in a subset of Schizophrenia patients with high inflammation
(C-reactive protein (CRP)>3 mg/L).